Erytech Pharma (ERYP) Coverage Initiated at Cowen
Separately, JMP Securities began coverage on shares of Erytech Pharma in a report on Friday. They issued an “outperform” rating and a $43.00 price objective on the stock.
Erytech Pharma (ERYP) traded up $1.61 during mid-day trading on Tuesday, hitting $29.36. 22,700 shares of the stock traded hands, compared to its average volume of 32,650. The company has a current ratio of 10.67, a quick ratio of 10.65 and a debt-to-equity ratio of 0.03. Erytech Pharma has a fifty-two week low of $24.59 and a fifty-two week high of $29.83.
Erytech Pharma Company Profile
Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells.
Receive News & Ratings for Erytech Pharma SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma SA and related companies with MarketBeat.com's FREE daily email newsletter.